Figure 2
![Figure 2. SHP2 inhibitor II-B08 inhibits the constitutive growth of human leukemic mast cell line HMC1.2 and human CD34+ cells bearing KITD816V as well as primary BM-derived AML blasts. (A) Human leukemic mast cell line HMC 1.2 or (B) human CD34+ cells transduced with KITD816V were starved for 6 hours in serum- and cytokine-free media and treated with indicated amounts of SHP2 inhibitor II-B08. After 48 hours, proliferation was evaluated by [3H] thymidine incorporation. Bars represent the mean thymidine incorporation (CPM ± SD) from 1 independent experiment performed in quadruplicate. *P < .001.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/120/13/10.1182_blood-2011-08-375873/4/zh89991295860002.jpeg?Expires=1724234814&Signature=HKsQa44eILyqOZIZd-2qS49xn92TJD1D9jryr~SsvSxYM4xKJtReaiXku-Gk~ClUtI~6OZtJXsKWp5UwLNiUjKA~BOMY5xydinE6QvDJI6ILUmH3Z9C07~VFeWqPJgLtltS2KQT32EbsXy78IBaVAbAu2niIsXf75yTowV43lSkEuynfPTHBuukBFtL-SwmWkb17zS44r17BMG3D7jYbOBNKx3kG6ouvSMLH0Rcoi7j4ayLv3mfdVv0jlg947xvpZFRUpay9Cyh0kkHUNefBLNtBp608h8nVUwl3X~SajJJXQNSocNv4iFfxNhDJVykS0rsM1qU8rXczbCIwGKR9Og__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
SHP2 inhibitor II-B08 inhibits the constitutive growth of human leukemic mast cell line HMC1.2 and human CD34+ cells bearing KITD816V as well as primary BM-derived AML blasts. (A) Human leukemic mast cell line HMC 1.2 or (B) human CD34+ cells transduced with KITD816V were starved for 6 hours in serum- and cytokine-free media and treated with indicated amounts of SHP2 inhibitor II-B08. After 48 hours, proliferation was evaluated by [3H] thymidine incorporation. Bars represent the mean thymidine incorporation (CPM ± SD) from 1 independent experiment performed in quadruplicate. *P < .001.
